Inhalation therapy for infants

Advanced Drug Delivery Reviews

Volumn 55, Issue 7, 2003, Pages 869-878

  Everard, Mark L ^a  

^a SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

Aerosols; Metered dose inhalers; Nebulizers; Pediatric pulmonary disease

Indexed keywords

AEROSOLS; BIOMEDICAL EQUIPMENT; DRUG PRODUCTS; PULMONARY DISEASES;

DRUG DELIVERY;

RESPIRATORY THERAPY;

ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; RIBAVIRIN;

AEROSOL; AIRWAY; ARTIFICIAL VENTILATION; COGNITION; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; EMOTION; GEOMETRY; HUMAN; INFANT; LUNG DISEASE; NOSE BREATHING; PARTICLE SIZE; PRIORITY JOURNAL; REPRODUCIBILITY; RESPIRATORY DISTRESS;

EID: 0038771127     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(03)00082-6     Document Type: Conference Paper

References (76)

1. Friegang B. New method of beclomethasone aerosol administration to children under 4 years of age. Can. Med. Assoc. J. 117:1977;1308-1309.
2. Technology Appraisal Guidance-No. 10, Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma. 2000;National Institute for Clinical Excellence, London.
3. Flores G., Horwitz R.I. Efficacy of beta2-agonists in bronchiolitis: a reappraisal and meta-analysis. Pediatrics. 100:1997;233-239.
4. Barrueto L., Mallol J., Figueroa L. Beclomethasone dipropionate and salbutamol by metered dose inhaler in infants and small children with recurrent wheezing. Pediatr. Pulmonol. 34:2002;52-57.
5. Burri P.H. Structural aspects of prenatal and postnatal development and growth of the lung. McDonald J.A. Lung Growth and Development. 1997;1-35 Marcel Dekker, New York.
6. Hutchinson A.A. Respiratory disorders of the neonate. Curr. Opin. Pediatr. 6:1994;142-153.
7. Murphy K., Aghajafari F., Hannah M. Antenatal corticosteroids for preterm birth. Semin. Perinatol. 25:2001;341-347.
8. Fok T.F., al-Essa M., Dolovich M., Rasid F., Kirpalani H. Nebulisation of surfactants in an animal model of neonatal respiratory distress. Arch. Dis. Child. Fetal Neonatal Ed. 78:1998;F3-F9.
9. T.P. Stevens, M. Blennow, R.F. Soll, Early surfactant administration with brief ventilation vs. selective surfactant and continued mechanical ventilation for preterm infants with or at risk for RDS, Cochrane Database Syst. Rev., 2002 CD003063.
10. A. Hislop A. Bronchopulmonary dysplasia: prenatal and postnatal influences. Pediatr. Pulmonol. 23:1997;71-75.
11. Copland I.B., Post M. Understanding the mechanisms of infant respiratory distress and chronic lung disease. Am. J. Respir. Cell Mol. Biol. 26:2002;261-265.
12. Cole C.J. Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease. Expert Opin. Investig. Drugs. 9:2000;53-67.
13. Halliday H.L. The effect of postnatal steroids on growth and development. J. Perinat. Med. 29:(4):2001;281-285. Review.
14. O'Shea T.M., Doyle L.W. Perinatal glucocorticoid therapy and neurodevelopmental outcome: an epidemiologic perspective. Semin. Neonatol. 6:2001;293-307.
15. Denny F.W. Jr. Viral infections of the lower respiratory tract. Taussig L., Landau L. Textbook of Paediatric Respiratory Medicine. 1998;Mosby, St. Louis.
16. Epidemiology of acute respiratory infections, in: P.D. Phelan, L.I. Landau, A. Olinski (Eds.), Respiratory Illness in Children, 2nd Edition, Blackwell Scientific, Oxford, 1998, pp. 29-50.
17. Everard M.L. Respiratory syncytial virus bronchiolitis and pneumonia. Taussig L., Landau L. Textbook of Paediatric Respiratory Medicine. 1998;Mosby, St. Louis.
18. Zambon M.C. J, Stockton J.D., Clewley J.P., Fleming D.M. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Lancet. 358:2001;1410-1416.
19. Griffin M.R., Coffey C.S., Neuzil K.M., Mitchel Jr E.F., Wright P.F., Edwards K.M. Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. Arch. Intern. Med. 162:2002;1229-1236.
20. Behrendt C.E., Decker M.D., Burch D.J., Watson P.H. International variation in the management of infants hospitalized with respiratory syncytial virus. Eur. J. Pediatr. 157:1998;215-220.
21. Palmer L.J., Rye P.J., Gibson N.A., Burton P.R., Landau L.I., Lesouef P.N. Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age. Am. J. Respir. Crit. Care Med. 163:2001;37-42.
22. Murakami G., Igarashi T., Adachi et al T. Measurement of bronchial hyperactivity in infants and preschool children using a new method. Ann. Allergy. 64:1990;383-387.
23. Martinez F. What have we learned from the Tucson Children's Respiratory Study? Pediatr. Respir. Rev. 3:2002;193.
24. Silverman M. Are all wheezing disorders in very young (preschool) children increasing in prevalence? Lancet. 357:2001;1821-1825.
25. Randolph A.G., Wang E.E. Ribavirin for respiratory syncytial virus infection of the lower respiratory tract. Cochrane Database Syst. Rev. 2:2000;. CD000181.
26. Everard M.L., Swarbrick A., Milner A.D. Effects of Ribavirin on respiratory morbidity and bronchial responsiveness during the first year post acute bronchiolitis. Respir. Med. 95:2001;275-278.
27. Elphick H.E., Ritson S., Rogers H., Everard M.L. When a 'wheeze' is not a wheeze - analysis of breath sounds in infancy. Eur. Respir. J. 16:2000;593-597.
28. Elphick H., Everard M.L. Noisy breathing in children. David T. Recent Advances in Paediatrics. 2002;The Royal Society of Medicine.
29. Elphick H.E., Ritson S., Everard M.L. Differential response of wheezes and ruttles to anticholinergics. Arch. Dis. Child. 86:2002;280-281.
30. Everard M.L., Le Souef P.N. Aerosol therapy and delivery systems. Taussig L., Landau L. Textbook of Paediatric Respiratory Medicine. 1998;Mosby, St. Louis.
31. Dolovich M.B., Everard M.L. Inhalation devices and techniques. Naspitz C.K., Szefler S.J., Tinkleman D., Warner J.O. Pediatric Asthma: an international perspective. 2001.
32. Giraud V., Roche N. Misuse of corticosteroid metered-dose inhaler is associated with decreased asthma stability. Eur. Respir. J. 19:2002;246-251.
33. Saunders K.B. Misuse of inhaled bronchoilator agents. Br. Med. J. 1:1965;1037-1038.
34. Crompton G. Problems patients have using pressurised aerosol inhalers. Eur. J. Resp. Dis. 119:(Suppl. 63):1982;101-104.
35. Hanania N., Wittman R., Kesten S. Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacer chambers and breath actuated dry powder inhalers. Chest. 105:1994;111-116.
36. Kamps A.W.A., van Ewijk B., Roorda R.J., P Brand P.L. Poor inhalation technique, even after inhalation instructions, in children with asthma. Pediatr. Pulmonol. 29:2000;39-42.
37. Milgrom H., Bender B., Ackerson L., Bowry P., Smith B., Rand C. Noncompliance and treatment failure in children with asthma. J. Allergy Clin. Immunol. 98:1996;1051-1057.
38. Everard M.L. CFC transition: the Emperor's new clothes. Thorax. 55:2000;811-814.
39. Borgstrom L., Bengtsson T., Derom E., Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int. J. Pharm. 193:2000;227-230.
40. Aswania O., Iqbal S.M., Ritson S., Everard M.L. Intra-subject variability in lung dose using five portable inhalers. Am. J. Respir. Crit. Care Med. 165:2002;A192.
41. Everard M.L. Aerosol delivery in infants and young children. J. Aerosol Med. 9:1996;71-77.
42. Becquiem M.H., Swift D.L., Bouchikhi A., Roy M., Teillac A. Particle deposition and resistance in the noses of adults and children. Eur. Respir. J. 4:1991;694-702.
43. Knight V., Yu C.P., Gilbert B.E., Divine G.W. Estimating the dosage of ribavirin aerosol according to age and other variables. J. Infect. Dis. 158:1988;443-448.
44. Morrow P.E., Yu C.P. Models of aerosol behavior in airways and alveoli. Moren F., Dolovich M.B., Newhouse M.T., Newman S.P. Aerosols in Medicine: Principles, Diagnosis and Therapy. 2nd Edition:1993;157-193 Elsevier Science, Amsterdam.
45. Xu J.B., Yu C.P. The effects of age on deposition of inhaled aerosols in the human lung. Aerosol Sci. Technol. 5:1986;349-357.
46. Hofmann W., Martonen T.B., Graham R.C. Predicted deposition of non-hydroscopic aerosols in the human lung as a function of age. J. Aerosol Med. 2:1989;49-68.
47. Phalen R.F., Oldham M.J. Methods for modeling particle deposition as a function of age. Respir. Physiol. 128:2001;119-130.
48. Harvey R.P., Hamby D.M. Age-specific uncertainty in particulate deposition for 1 microm AMAD particles using the ICRP 66 lung model. Health Phys. 82:2002;807-816.
49. Schiller-Scotland C.F., Hlawa R., Gebhart J. Experimental data for total deposition in the respiratory tract of children. Toxicol. Lett. 72:1994;137-144.
50. Nerbrink O.L., Lindstrom M., Meurling L., Svartengren M. Inhalation and deposition of nebulized sodium cromoglycate in two different particle size distributions in children with asthma. Pediatr. Pulmonol. 34:2002;351-360.
51. Chua H.L., Collis G.C., Newbury et al A.M. The influence of age on aerosol deposition in children with cystic fibrosis. Eur. Respir. J. 7:1994;2185-2191.
52. Tal A., Golan H., Aviram M. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J. Pediatr. 128:1996;479-484.
53. Fok T., Monkman S., Dolovich M. Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia. Paediatr. Pulmonol. 21:1996;3101-3109.
54. Tal A., Golan H., Grauer N., Aviram M., Albin D., Quastel M.R. Deposition pattern of radiolabeled salbutamol inhaled from a metered-dose inhaler by means of a spacer with mask in young children with airway obstruction. J. Pediatr. 128:1996;479-484.
55. Murakam G., Igarashi T., Adachi Y. Measurement of bronchial hyperactivity in infants and preschool children using a new method. Ann. Allergy. 64:1990;383-387.
56. Mallol J., Rattray S., Walker G., Cook D., Robertson C.F. Aerosol deposition in infants with cystic fibrosis. Pediatr. Pulmonol. 21:1996;276-281.
57. Amirav I., Balanov I., Gorenberg M., Luder A.S., Newhouse M.T., Groshar D. Beta-agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants. J. Nucl. Med. 43:2002;487-491.
58. Salmon B., Wilson N.M., Silverman M. How much aerosol reaches the lungs of wheezy infants and toddlers? Arch. Dis. Child. 65:1990;401-403.
59. Iles R., Lister P., Edmunds A.T. Crying significantly reduces absorption of aerosolised drug in infants. Arch. Dis. Child. 81:1999;163-165.
60. Everard M.L., Hardy J.G., Milner A.D. Comparison of nebulised aerosol deposition in the lungs of health adults following oral and nasal inhalation. Thorax. 48:1993;1045-1046.
61. Diot P., Palmer L.B., Smaldone A., DeCelie-Germana J., Grimson R., Smaldone G.C. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am. J. Respir. Crit. Care Med. 156:1997;1662-1668.
62. Everard M.L., Clark A.R., Milner A.D. Drug delivery from jet nebulisers. Arch. Dis. Child. 67:1992;586-591.
63. Amirav I., Newhouse M.T. Aerosol therapy with valved holding chambers in young children: importance of the facemask seal. Pediatrics. 108:2001;389-394.
64. Sangwan S., Gurses B.K., Smaldone G.C. Effect of facemask and nebuliser on drug delivery and face deposition in children. Am. J. Respir. Crit. Care Med. 165:2002;A744.
65. Everard M.L. Delivering drugs to the lungs of upset children is a thankless task. Arch. Dis. Child. 82:2000;428.
66. Nikander K. Adaptive aerosol delivery: the principles. Eur. Respir. Rev. 7:(51):1997;385-387.
67. Berg E., Madsen J., Bisgaard H. In vitro performance of three combinations of spacers and pressurized metered dose inhalers for treatment in children. Eur. Respir. J. 12:1998;472-476.
68. Janssens H.M., de Jongste J.C., Fokkens W.J., Robben S.G., Wouters K., Tiddens H.A. The Sophia Anatomical Infant Nose-Throat (Saint) model: a valuable tool to study aerosol deposition in infants. J. Aerosol Med. 14:2001;433-441.
69. Ivanovich M., Kreamer J.W., Gritzalis D., Moses J. Evaluation of an auditory feedback equipped metered dose inhaler. Am. J. Ther. 3:1996;818-820.
70. Everard M.L. Radiolabelled deposition studies in childhood. Thorax. 49:1994;1259-1266.
71. Mell A., Himmelmann A., Jendle J., Wollmer P. Pharmacokinetics and intra-subject variability of inhaled insulin in healthy smokers and non-smokers. Diabetes. 50:2001;A126.
72. Janssens H.M., Devadason S.G., Hop W.C., LeSouef P.N., De Jongste J.C., Tiddens H.A. Variability of aerosol delivery via spacer devices in young asthmatic children in daily life. Eur. Respir. J. 13:1999;787-791.
73. Khalaf M.N., Hurley J.F., Bhandari V. A prospective controlled trial of albuterol aerosol delivered via metered dose inhaler-spacer device (MDI) versus jet nebulizer in ventilated preterm neonates. Am. J. Perinatol. 18:2001;169-174.
74. Everard M.L., Stammers J., Hardy J.G., Milner A.D. New aerosol delivery system for neonatal ventilator circuits. Arch. Dis. Child. 67:1992;826-830.
75. Dubus J.C., Rhem R., Monkman S., Dolovich M. Delivery of salbutamol pressurized metered-dose inhaler administered via small-volume spacer devices in intubated, spontaneously breathing rabbits. Pediatr. Res. 50:2001;384-389.
76. Turpeinen M., Nikander K. Nebulisation of a suspension of budesonide and a solution of terbutaline into a neonatal ventilator circuit. Respir. Care. 46:2001;43-48.